Polaris Market Research presents its latest market research report, titled Age-Related Macular Degeneration (AMD) Market. It is a comprehensive market research report analyzing the fast-evolving age-related macular degeneration (AMD) market. The report offers insight into the current market landscape, drivers for growth, emerging trends, competitive dynamics, and future scope for growth. The study combines qualitative and quantitative analysis, giving insights about the size of the market, segments, regional performance, and industry developments. By going through the report, stakeholders can get an in-depth overview of the age-related macular degeneration (AMD) market and its outlook during the forecast period.

age-related macular degeneration (AMD) Market Key Takeaways

• The age-related macular degeneration (AMD) market size was valued at USD 12.64 billion in 2025.
• The market is estimated to reach USD 25.18 billion by 2034.
• The market is projected to witness a CAGR of 8.0% from 2026 to 2034.
• The wet AMD segment held 85.6% of the market share in 2025.
• The Eylea segment held 43.2% of the market share by drugs in 2025.
• The North America region held 52.65% of market share in 2025.
• The Asia Pacific region is expected to register strong growth during the forecast period, supported by its high AMD prevalence.

What is the age-related macular degeneration (AMD) Market?

The age-related macular degeneration market covers the research, development, manufacturing, and supply of diagnostics and therapeutics used to treat AMD, a progressive eye disease that damages central vision and predominantly affects people aged 50 and older. The market spans both wet and dry forms of the condition, with anti-VEGF injections currently serving as the mainstay treatment for wet AMD.

Market Dynamics

The report examines the key market dynamics influencing the growth and development of the age-related macular degeneration (AMD) market. It analyzes the market drivers, market opportunities, market trends, and restraints that might impact the growth of the market.

Key Market Driver: Increasing Geriatric Population

The rapid growth of the world's elderly population is expanding the pool of patients susceptible to AMD-related vision loss. As life expectancy continues to rise and the number of people aged 60 and above climbs, demand for AMD diagnosis and treatment is expected to grow correspondingly across both developed and developing regions.

Market Opportunity: R&D Focus on Dry AMD Treatments

Dry AMD remains a comparatively underserved segment relative to wet AMD, creating an opening for companies investing in complement pathway inhibitors and other emerging therapies. Continued research in this area offers a meaningful opportunity to expand treatment options for the more prevalent but less pharmacologically addressed form of the disease.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/global-age-related-macular-degeneration-amd-market 

Emerging Market Trend: Gene Therapy and AI-Based Diagnostics

Emerging gene and stem-cell therapies are being explored as longer-term alternatives to repeated anti-VEGF injections, aiming to preserve or restore retinal function. At the same time, AI-powered analysis of retinal imaging is enabling earlier detection and more personalized monitoring of disease progression, supporting a shift toward more proactive AMD management.

Market Challenge: High Cost of AMD Medicines

The cost of anti-VEGF therapies and emerging biologic treatments remains a barrier to access in many markets, particularly where healthcare reimbursement is limited. This cost pressure can restrict treatment uptake even as clinical need continues to grow with an aging population.

How Is Market Segmentation Done?

The research gives an in-depth segmental analysis of the age-related macular degeneration (AMD) industry. The segmentation in the market has been done on the basis of product, drugs, route of administration, and distribution channel. This research assesses the contribution of each segment and pinpoints the segments driving the present-day demand and those that will grow strongly during the forecast period. This analysis helps stakeholders analyze evolving demand trends and recognize promising market opportunities.

Which Region Leads Market Demand?

The report includes a regional analysis of the age-related macular degeneration (AMD) market, covering North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market dominates the overall market, attributed to a high prevalence of AMD within its aging population, strong patient awareness, and significant participation from key market players in research and development. Further, the Asia Pacific market is expected to witness significant growth during the forecast period, influenced by a substantial and growing share of the global AMD patient population, even as drug accessibility and affordability continue to develop across the region. In addition to this, there is an analysis of regional demand, investments, infrastructure, regulatory environment, technology penetration, and industry development.

Who Are the Key Market Players?

The report presents a detailed competitive analysis of the age-related macular degeneration (AMD) industry. Player positioning and strategy, such as new product/service launches, partnerships, mergers and acquisitions, geographic expansion, capacity expansion, and technological developments, have been analyzed. The report also examines the competitive structure of the industry and how organizations are responding to changing consumer demands.

A few of the key players in the market include:

• Acucela Inc.
• Alimera Sciences Inc.
• ALLERGAN
• Bausch & Lomb Incorporated
• Bayer AG
• F. Hoffmann La Roche
• GlaxoSmithKline PLC
• Novartis AG
• Ophthotech Corporation
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Rxi Pharmaceuticals Inc.
• Santen Pharmaceuticals Co.
• Valeant Pharmaceuticals International

Future Outlook

The AMD market is expected to keep growing through 2034 as the global geriatric population expands and treatment innovation continues. Longer-acting anti-VEGF formulations, complement pathway inhibitors, and gene-therapy approaches are likely to reshape the treatment landscape, while AI-enabled diagnostics support earlier detection and more personalized patient management across both developed and emerging markets.

More Trending Latest Reports By Polaris Market Research:

bim-transforming-future-of-construction

e-learning-market

styrene-butadiene-rubber-latex-is-a-versatile-material-for-modern-manufacturing

chlorinated-polyvinyl-chloride-cpvc-market

edge-ai-market

medical-aesthetics-market

sunglasses-market

water-treatment-chemicals-market

aesthetic-exosomes-market